Updated:
Sana Biotechnology
Sana Biotechnology develops engineered cell therapies to repair, control, or replace cells, targeting diabetes, B-cell cancers, and autoimmune disorders.
Sana Biotechnology
Sana is creating engineered cells to repair and control genes in cells or replace missing or damaged cells to solve the underlying causes of disease.
General information
Firm type
other
Location
Region
North America
Country
United States
City
Seattle
Corporate office
Seattle, WA, United States
Additional offices
South San Francisco, CA, United States · Cambridge, MA, United States
Sector focus
Frequently asked questions
What is Sana Biotechnology's core therapeutic focus?
Sana develops engineered cell therapies designed to repair and control genes in cells or replace missing or damaged cells. Its pipeline targets diabetes, B-cell cancers, and B-cell related autoimmune disorders (per the firm's public statements).
Is Sana Biotechnology a family office or asset manager?
No. Sana is a publicly traded biotechnology company, not a family office or asset manager. It operates under corporate governance and reports to public shareholders through SEC filings.
Where does Sana operate its research and development?
Sana maintains three US offices: a Seattle headquarters (188 East Blaine Street, Suite 350, Seattle, WA 98102), a South San Francisco site (1 Tower Place, Suite 500, South San Francisco, CA 94080), and a Cambridge site (300 Technology Square, Suite 700, Cambridge, MA 02139), per its website.
What technologies does Sana use in its drug development?
The firm combines cellular biology, machine learning, and therapeutic development expertise. It applies these to engineering cells to act as medicines, targeting genetic and cellular origins of disease.
Who leads Sana Biotechnology?
The firm's leadership is not publicly detailed on its website or in available sources. Sana's executive team is expected to be disclosed in its SEC filings and annual reports.
How is Sana Biotechnology structured differently from a typical family office?
Sana is a publicly traded corporation focused on drug development, not capital management. It does not manage external capital or operate investment vehicles. Its governance and financial disclosures are those of a public biotech firm.
Does Sana Biotechnology have a philanthropic arm?
Not publicly disclosed. The firm's website includes a patient advocacy contact (patientadvocacy@sana.com) but does not mention a separate foundation or philanthropic structure.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: